{
    "id": "NCLEX_NGN_SA_5001",
    "questionType": "selectAll",
    "scoring": "polytomous",
    "difficulty": "Hard",
    "topic": "Pharmacological and Parenteral Therapies",
    "subtopic": "Thrombolytic Therapy Contraindications",
    "bloom": "Analyzing",
    "caseId": "MISSION-500-24-1771345273411",
    "prompt": "The nurse is preparing to administer alteplase (tPA) to a client diagnosed with an acute ischemic stroke. The nurse reviews the electronic health record. Which findings require the nurse to immediately contact the provider and question the administration of alteplase? Select all that apply.",
    "tabs": [
        {
            "title": "Nurses' Notes",
            "content": "Date/Time: Today, 1145\n\n68-year-old male arrived via EMS with stroke alert activation. Partner is at bedside. Partner states client was last seen normal at 0800 while reading the morning newspaper. At 1030, partner found client slouched in his chair with expressive aphasia and inability to lift his right arm. Partner reports delaying the call to EMS due to concerns about hospital costs. Initial NIH Stroke Scale (NIHSS) is 16. Non-contrast head CT completed. Partner confirms client took his last dose of apixaban 'last night before bed'."
        },
        {
            "title": "Vital Signs",
            "content": [
                {
                    "time": "1120 (On Arrival)",
                    "BP": "192/108 mmHg",
                    "HR": "98/min (Atrial Fibrillation)",
                    "RR": "18/min",
                    "SpO2": "96% on room air"
                },
                {
                    "time": "1135 (Post Labetalol 10 mg IV)",
                    "BP": "178/98 mmHg",
                    "HR": "92/min (Atrial Fibrillation)",
                    "RR": "18/min",
                    "SpO2": "97% on room air"
                },
                {
                    "time": "1145 (Current)",
                    "BP": "175/96 mmHg",
                    "HR": "90/min (Atrial Fibrillation)",
                    "RR": "16/min",
                    "SpO2": "98% on room air"
                }
            ]
        },
        {
            "title": "Laboratory Results",
            "content": [
                {
                    "test": "Glucose, Point-of-Care",
                    "value": "145 mg/dL",
                    "reference": "70-110 mg/dL"
                },
                {
                    "test": "Platelet Count",
                    "value": "88,000/mm続",
                    "reference": "150,000-450,000/mm続"
                },
                {
                    "test": "INR",
                    "value": "1.2",
                    "reference": "0.8-1.1"
                },
                {
                    "test": "Potassium",
                    "value": "4.1 mEq/L",
                    "reference": "3.5-5.0 mEq/L"
                },
                {
                    "test": "Creatinine",
                    "value": "1.3 mg/dL",
                    "reference": "0.6-1.2 mg/dL"
                }
            ]
        },
        {
            "title": "Diagnostics",
            "content": "Test: Non-Contrast Head CT\n\nResult: No evidence of acute intracranial hemorrhage. Mild, age-related cerebral volume loss."
        }
    ],
    "options": [
        {
            "id": "opt5",
            "text": "NIHSS score of 16"
        },
        {
            "id": "opt6",
            "text": "INR of 1.2"
        },
        {
            "id": "opt4",
            "text": "Last dose of apixaban taken the previous night"
        },
        {
            "id": "opt1",
            "text": "Blood pressure of 175/96 mmHg"
        },
        {
            "id": "opt2",
            "text": "Platelet count of 88,000/mm続"
        },
        {
            "id": "opt3",
            "text": "Time of onset 3 hours 45 minutes ago"
        }
    ],
    "correctAnswer": [
        "opt2",
        "opt4"
    ],
    "answerBreakdown": [
        {
            "optionId": "opt1",
            "isCorrect": false,
            "rationale": "Incorrect. The guidelines for alteplase administration require blood pressure to be maintained below 185/110 mmHg. Although the client's initial BP was too high, it has been treated with labetalol and is now within the acceptable range. Therefore, this finding does not contraindicate tPA administration."
        },
        {
            "optionId": "opt2",
            "isCorrect": true,
            "rationale": "Correct. A platelet count less than 100,000/mm続 is an absolute contraindication for alteplase administration due to the significantly increased risk of intracranial hemorrhage and other severe bleeding complications. The nurse must recognize this critical lab value and immediately contact the provider to halt the treatment."
        },
        {
            "optionId": "opt3",
            "isCorrect": false,
            "rationale": "Incorrect. The standard window for administering alteplase for an acute ischemic stroke is within 3 to 4.5 hours from the last known normal time. With the last known normal at 0800 and the current time at 1145, the elapsed time is 3 hours and 45 minutes, which is within the acceptable window. This is an indication for treatment, not a contraindication."
        },
        {
            "optionId": "opt4",
            "isCorrect": true,
            "rationale": "Correct. Apixaban is a direct factor Xa inhibitor. The use of direct thrombin inhibitors or direct factor Xa inhibitors within the last 48 hours is an absolute contraindication for alteplase therapy, as it dramatically increases the risk of life-threatening hemorrhage. The client's INR may be normal, which can be a misleading factor, making this a critical safety finding the nurse must identify."
        },
        {
            "optionId": "opt5",
            "isCorrect": false,
            "rationale": "Incorrect. An NIHSS score of 16 indicates a moderate-to-severe stroke with significant neurological deficits. This score is a strong indication for thrombolytic therapy, not a contraindication. The goal of tPA is to reverse or minimize deficits in such clients."
        },
        {
            "optionId": "opt6",
            "isCorrect": false,
            "rationale": "Incorrect. An INR greater than 1.7 is a contraindication for alteplase, typically relevant for clients on warfarin. An INR of 1.2 is within the acceptable range. It is also not a reliable measure of anticoagulation for a client taking apixaban, making the history of medication use the more critical piece of data."
        }
    ]
}